Cargando…

The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study

Systemic sclerosis (SSc) is an immune-mediated connective tissue disease. Recent studies reported differences in the composition of intestinal microbiota (dysbiosis) in patients with SSc compared to nonsclerodermic subjects. Dysbiosis may disrupt the intestinal barrier, which leads to immunological...

Descripción completa

Detalles Bibliográficos
Autores principales: Stec, Albert, Maciejewska, Magdalena, Zaremba, Michał, Paralusz-Stec, Karolina, Michalska, Milena, Rudnicka, Lidia, Sikora, Mariusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141873/
https://www.ncbi.nlm.nih.gov/pubmed/37109064
http://dx.doi.org/10.3390/jpm13040678
_version_ 1785033479433486336
author Stec, Albert
Maciejewska, Magdalena
Zaremba, Michał
Paralusz-Stec, Karolina
Michalska, Milena
Rudnicka, Lidia
Sikora, Mariusz
author_facet Stec, Albert
Maciejewska, Magdalena
Zaremba, Michał
Paralusz-Stec, Karolina
Michalska, Milena
Rudnicka, Lidia
Sikora, Mariusz
author_sort Stec, Albert
collection PubMed
description Systemic sclerosis (SSc) is an immune-mediated connective tissue disease. Recent studies reported differences in the composition of intestinal microbiota (dysbiosis) in patients with SSc compared to nonsclerodermic subjects. Dysbiosis may disrupt the intestinal barrier, which leads to immunological activation via microbial antigen and metabolite translocation. The study aimed to assess the differences in intestinal permeability between SSc patients and controls and to examine the correlation between intestinal permeability and complications of SSc. The study comprised 50 patients with SSc and 30 matched subjects. Serum intestinal permeability markers: intestinal fatty acid binding protein, claudin-3, and lipopolysaccharides (LPS) were determined using an enzyme-linked immunosorbent assay. SSc patients had a significantly increased concentration of LPS compared to control subjects (232.30 [149.00–347.70] versus 161.00 [83.92–252.20] pg/mL, p < 0.05). The patients with shorter SSc duration (≤6 years) had an increased concentration of LPS and claudin-3 compared to the subgroup with longer disease length: LPS (280.75 [167.30–403.40] versus 186.00 [98.12–275.90] pg/mL, p < 0.05), and claudin-3 (16.99 [12.41–39.59] versus 13.54 [10.29–15.47] ng/mL, p < 0.05). The patients with esophageal dysmotility had a decreased LPS level compared to those without this complication (188.05 [102.31–264.40] versus 283.95 [203.20–356.30] pg/mL, p < 0.05). Increased intestinal permeability in SSc may exacerbate the course of the disease and increase the risk of developing complications. Lower LPS levels in SSc might be a hallmark of esophageal dysmotility.
format Online
Article
Text
id pubmed-10141873
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101418732023-04-29 The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study Stec, Albert Maciejewska, Magdalena Zaremba, Michał Paralusz-Stec, Karolina Michalska, Milena Rudnicka, Lidia Sikora, Mariusz J Pers Med Article Systemic sclerosis (SSc) is an immune-mediated connective tissue disease. Recent studies reported differences in the composition of intestinal microbiota (dysbiosis) in patients with SSc compared to nonsclerodermic subjects. Dysbiosis may disrupt the intestinal barrier, which leads to immunological activation via microbial antigen and metabolite translocation. The study aimed to assess the differences in intestinal permeability between SSc patients and controls and to examine the correlation between intestinal permeability and complications of SSc. The study comprised 50 patients with SSc and 30 matched subjects. Serum intestinal permeability markers: intestinal fatty acid binding protein, claudin-3, and lipopolysaccharides (LPS) were determined using an enzyme-linked immunosorbent assay. SSc patients had a significantly increased concentration of LPS compared to control subjects (232.30 [149.00–347.70] versus 161.00 [83.92–252.20] pg/mL, p < 0.05). The patients with shorter SSc duration (≤6 years) had an increased concentration of LPS and claudin-3 compared to the subgroup with longer disease length: LPS (280.75 [167.30–403.40] versus 186.00 [98.12–275.90] pg/mL, p < 0.05), and claudin-3 (16.99 [12.41–39.59] versus 13.54 [10.29–15.47] ng/mL, p < 0.05). The patients with esophageal dysmotility had a decreased LPS level compared to those without this complication (188.05 [102.31–264.40] versus 283.95 [203.20–356.30] pg/mL, p < 0.05). Increased intestinal permeability in SSc may exacerbate the course of the disease and increase the risk of developing complications. Lower LPS levels in SSc might be a hallmark of esophageal dysmotility. MDPI 2023-04-18 /pmc/articles/PMC10141873/ /pubmed/37109064 http://dx.doi.org/10.3390/jpm13040678 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stec, Albert
Maciejewska, Magdalena
Zaremba, Michał
Paralusz-Stec, Karolina
Michalska, Milena
Rudnicka, Lidia
Sikora, Mariusz
The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study
title The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study
title_full The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study
title_fullStr The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study
title_full_unstemmed The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study
title_short The Clinical Significance of Serum Biomarkers of the Intestinal Barrier in Systemic Sclerosis: A Cross-Sectional Study
title_sort clinical significance of serum biomarkers of the intestinal barrier in systemic sclerosis: a cross-sectional study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141873/
https://www.ncbi.nlm.nih.gov/pubmed/37109064
http://dx.doi.org/10.3390/jpm13040678
work_keys_str_mv AT stecalbert theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy
AT maciejewskamagdalena theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy
AT zarembamichał theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy
AT paraluszsteckarolina theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy
AT michalskamilena theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy
AT rudnickalidia theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy
AT sikoramariusz theclinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy
AT stecalbert clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy
AT maciejewskamagdalena clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy
AT zarembamichał clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy
AT paraluszsteckarolina clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy
AT michalskamilena clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy
AT rudnickalidia clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy
AT sikoramariusz clinicalsignificanceofserumbiomarkersoftheintestinalbarrierinsystemicsclerosisacrosssectionalstudy